Skip to main content

Table 2 Summary of adverse events

From: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis

  Overall (N = 8)
AE Categories n (%) Events
Any AE 8 (100.0) 71
Any SAE 1 (12.5) 1
Fatal TEAEs 0 (0.0) 0
TEAEs or TESAEs resulting in drug discontinuation 0 (0.0) 0
TEAEs or TESAEs resulting in study discontinuation 0 (0.0) 0
Meningococcal infections 0 (0.0) 0
Treatment-related AEs (all considered possibly-related) 2 (25.0) 3
  1. AE adverse event, SAE serious adverse event, TEAE treatment-emergent adverse event, TESAE treatment-emergent serious adverse event